Abby Reinhard

Invesitgators from the SoSTART trial recommend further research into whether oral anticoagulation use is superior to aversion to it for preventing symptomatic major vascular events.

Data indicate that noncontrast CT may be an alternative to CTP or MRI for patients with proximal anterior circulation occlusion stroke who are candidates for mechanical thrombectomy.

Data further suggest a potential weak association between impulsivity and suicidality in this patient population.

Anita Shelgikar, MD, MHPE, discussed a recent study from which data suggested a statistically significant improvement in sleep medicine knowledge following a 2-day introductory course.

Mona Bostick, RDN, LDN, MSCS, reflected on the past year in multiple sclerosis care, offering her opinion on the importance of diet and science-based nutritional approaches.

The study called for additional prospective studies to address therapy timing and outcome measurements for the treatments used in the clinic.

Two patients with late infantile GM1 gangliosidosis in Cohort 1 received a low dose of the treatment, reporting no serious adverse events. Passage Bio noted it plans to move forward with 2 additional cohorts.

The study had a relatively high proportion of Black and Hispanic participants, with higher MCI among these patients.

The FDA has placed the investigational new drug application for the treatment on clinical hold.

The treatment was well-tolerated in children with AS, positively affecting constipation, a common symptom of the condition.

The phase 4 study will enroll 300 patients with amyotrophic lateral sclerosis who have started treatment with edaravone (Radicava; Mitsubishi Tanabe Pharma America).

Amy Kunchok, MD, staff neurologist at the Mellen Center for Multiple Sclerosis and Research at Cleveland Clinic, discussed a recent talk she gave that highlighted the different phenotypes of AQP-IgG NMOSD and MOGAD.

Pharma Two B anticipates filing a new drug application to the FDA for the investigational treatment in 2022.

Two parallel studies will evaluate the BioXcel Therapeutics’ drug’s effectiveness as an acute therapy in treating a full spectrum of agitation in 300 patients with AD.

Findings represent the most comprehensive metabolic profiling of this patient population as a function of body mass index.

Clinicians have begun to incorporate more holistic ways to approach the treatment of multiple sclerosis symptoms by focusing on better overall health, exercising, and dieting.

The FDA has set a prescription drug user fee act goal date of September 28, 2022, for the investigational treatment from TG Therapeutics.

Chris Kalafatis, MD, MRCPsych, discussed a new tool, the Integrated Cognitive Assessment, developed by Cognetivity, and its potential for patients with dementias and multiple sclerosis.

Results from a recent study further suggest that using digital cognitive behavior therapy for insomnia, or dCBT-I, during pregnancy may be effective in preventing postpartum depression and anxiety.

Investigators used cross-sectional data from the observational population-based cohort of the Maastricht Study, calculating LIBRA scores with 12 dementia risk and protective factors.

Statistical significance was observed for both the MycarinG study’s primary and secondary end points in a population of 200 patients with myasthenia gravis treated with the UCB agent.

Kent Pryor, PhD, the CEO of ZZ Biotech, provided insight into a phase 2 trial that will evaluate the safety and efficacy of the investigational treatment in 16 patients with amyotrophic lateral sclerosis.

Results from the cohort study contrast with reports in multiple sclerosis, finding that new remission silent lesions were rare in both myelin oligodendrocyte glycoprotein antibody disease and aquaporin-4 antibody neuromyelitis optica spectrum disorder.

The cohort study was conducted using data from the Danish Multiple Sclerosis Registry for women with clinically isolated syndrome and relapsing remitting multiple sclerosis.

Adverse effects were common but manageable among patients and were not identified as a reason to discontinue treatment in those with refractory disease.

Investigators included 1059 patients from a population-based multidisciplinary Greek study aimed as estimating dementia epidemiology in the aging population.

Investigators suggest further studies to better determine is NPC had measurable benefits for patient quality of life.

The FDA has previously granted the Acadia Pharmaceuticals treatment fast track status and orphan drug designation for Rett syndrome.

Prespecified and post hoc analyses explored the heterogeneity of disease at baseline, with meaningful treatment effect indicated in a subset of patients with less severe ALS.

Findings presented at AES 2021 included data from children with tuberous sclerosis complex and drug refractory epilepsy who were not candidates for epilepsy surgery.